While vaccine makers insist that any vaccine reaching the market will have undergone rigorous testing, the way trial protocols are designed suggests these vaccines may leave a lot to be desired.

As reported1 by Forbes contributor William Haseltine, a former professor at Harvard Medical School and Harvard School of Public Health, while Moderna, Pfizer, AstraZeneca and Johnson & Johnson have all published their vaccine trial protocols in a rare display of transparency, "close inspection of the protocols raises surprising concerns."

In a nutshell, the trial designs are such that the vaccines will get a passing grade even if their efficacy is minimal. Of course, we must also consider vaccine side effects and I've also written several articles about mounting safety concerns.